. 2022 Apr 4;9(2):88–92. doi: 10.5152/eurjrheum.2022.21063
Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.Table 2.
Effect Estimates for Main Study Outcomes
| Outcome | Relative Risk (95% CI) | NNT (95% CI) | P | |
|---|---|---|---|---|
| Disease severity | Death | 0.45 (0.09-2.1) | 16.14 (18.5 (harm) to ∞ to 5.6 (benefit)) | .3 |
| Relapse | 0.8 (0.3-1.8) | 21.3 (8.3 (harm) to ∞ to 4.7 (benefit) | .6 | |
| Pulmonary involvement a | 0.46 (0.01-11) | 66 (22-13) | .6 | |
| Renal involvement (CKD) b | 0.22 (0.02-1.8) | 11.4 (48.547 (harm) to ∞ to 5.109 (benefit)) | .1 | |
| Renal involvement (ESRD) c | 0.54 (0.11-2.6) | 23 (15.100 (harm) to ∞ to 6.564 (benefit)) | .4 | |
| Peripheral neuropathyd | 1.3 (0.08-21) | 147 | .8 | |
| Overall rate of complications | 0.45 (0.1-1.2) | 8 (32.442 (harm) to ∞ to 3.590 (benefit)) | .1 | |
| Medication adverse effects | 0.67 (0.06-7.2) | 82 (16.312 (harm) to ∞ to 11.696 (benefit)) | .7 | |
a
Including lung parenchymal nodules, interstitial lung disease, and alveolar hemorrhage.
b
Any type of renal involvement without end-stage renal disease and including glomerulonephritis, proteinuria, or hematuria with or without impaired renal function.
c
Severely impaired renal function needing dialysis.
d
Neuropathy resulting in glove and/or stocking distribution of sensory loss.
CKD, chronic kidney disease; CI, confidence interval; ESRD, end-stage renal disease; NNT, number need to treat.